Chlorhexidine for skin antisepsis: making the case to keep peripheral venous catheters CLEAN

Affiliations

¹ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC, USA; Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
² Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC, USA; Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: deverick.anderson@duke.edu.

Comment

Sonali D Advani et al. Lancet Infect Dis. 2021 Jul.

. 2021 Jul;21(7):902-903.

doi: 10.1016/S1473-3099(20)30716-7. Epub 2021 Feb 1.

¹ Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC, USA; Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA.
² Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, NC, USA; Division of Infectious Diseases, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: deverick.anderson@duke.edu.

No abstract available

Comment on

Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial.
Guenezan J, Marjanovic N, Drugeon B, Neill RO, Liuu E, Roblot F, Palazzo P, Bironneau V, Prevost F, Paul J, Pichon M, Boisson M, Frasca D, Mimoz O; CLEAN-3 trial investigators. Guenezan J, et al. Lancet Infect Dis. 2021 Jul;21(7):1038-1048. doi: 10.1016/S1473-3099(20)30738-6. Epub 2021 Feb 1. Lancet Infect Dis. 2021. PMID: 33539734 Clinical Trial.